OMF is fundraising to support open, collaborative research to find effective treatments and diagnostic markers for ME/CFS, Long COVID, and related diseases.

California, USA
Joined December 2012
Join the Long COVID International Conference 2026 and be part of the conversation! Attend in person in Nice, France, or join virtually from anywhere in the world. 👉 Register today: amededu.co/3U3aDr1 #LongCOVIDIntl @AcademicMedicalEducation
3
7
294
RECOVER-TLC’s third annual hybrid workshop is Nov. 4–5, 2026 — in person at The Bethesdan in Bethesda, MD, or virtually via Zoom. 🔗 Register (free): ow.ly/klSM50ZZxs9
1
5
386
Dr. Danielle Meadows shares OMF’s CTN Lite survey results on post-exertional symptom worsening in ME/CFS and how patient feedback is shaping decentralized, precision-medicine, patient-centered clinical trials. 👉 Watch the webinar recordings: youtube.com/watch?v=iq1Fcfey…
5
19
727
OMF Founder & CEO Linda Tannenbaum visited OMF’s ME/CFS Collaborative Research Center at Montreal earlier this month. Each member presented their work. “They are excited about their own research,” Linda said. That energy fuels everything we do. 💙
1
16
445
A treatment's mechanism of action is the specific biological process by which it produces its effect in the body. Understanding mechanism of action helps clinicians make smarter, more personalized treatment choices for people living with ME/CFS & Long COVID.
2
1
6
596
OMF's Collaborative Center at Montreal is trialing treatments that target specific biological differences found in #MECFS based on what we already know of a drug’s mechanism of action. 🔗 Read more about this project: ow.ly/HOZM50ZXoUs
2
5
173
Why do people with Long COVID and ME/CFS wake up unrefreshed, even when a standard sleep study looks close to normal? A 2026 study in the journal SLEEP points to the fine-grained structure of sleep itself.
1
10
11
631
In this Journal Club, Dr. Danielle Meadows walks through "Facility-Measured Sleep Electroencephalographic Microstructures in Long COVID" (Sun et al., 2026), a paper from Dr. Janet Mullington's team in collaboration with OMF's Computational Research Center for Complex Diseases.
1
1
7
171
Today is DAF Day, a day dedicated to the power of Donor-Advised Funds to make a difference. You can multiply your impact by directing a grant from your DAF to OMF to fuel critical research into #MECFS and #LongCOVID. 👉 Recommend your grant for DAF Day: ow.ly/CBUv50ZVTN3
1
2
1
11
411
Multi-omics is a style of research that combines multiple layers of biological data—including genomics (genes), proteomics (proteins), and metabolomics (metabolites)---to build a complete picture of what is happening inside the body.
1
2
9
516
OMF’s Collaborative Center at Montreal is using this in their Multi-Omic Approaches to Solve Post-Acute COVID-19 (MOSAIC) project, which is trying to facilitate early detection of ME/CFS in people with #LongCOVID and better understand disease progression.
1
4
124
It's #Cartober! 🚗 Turn your unwanted vehicle into vital research funds for #MECFS & #LongCOVID. Your donation is simple, hassle-free, and 100% tax-deductible. Get started👉 careasy.org/nonprofit/Open-M…
3
318
The 2026 Stanford Community Symposium recordings are now on YouTube. Every talk is now online, including Danielle Meadows, PhD, OMF's VP of Research Programs and Operations, on the clinical trial landscape in ME/CFS and Long COVID. ▶️ ow.ly/I7qV50ZSFYx
15
1
21
924
👉 Dr. Danielle Meadows, OMF's VP of Research Programs, will walk through the results in a live webinar on October 7 at 3 PM ET. 🔗 Register: ow.ly/Hgom50ZS0R2 🔗 Learn more: ow.ly/OOjT50ZS0R4 A recording goes out to everyone who signs up!
7
3
14
831
Nearly 1,700 of you completed our deep dive survey on post-exertional symptom worsening. In the survey we presented two frameworks: a staged model of post-exertional worsening, and a proposed set of outcome measures for decentralized treatment trials.
1
4
8
564
These survey results go directly into CTN Lite trial design, and we continue to learn from patterns in your responses. They shape the outcome measures we select, the way we define and track PEM, and how we build trial protocols that can accommodate patients
1
1
145